Hideo-Kajita A, et al. - Researchers assessed the impact of administering cangrelor (a direct, rapid-onset acting intravenous P2Y₁₂ receptor inhibitor) immediately before percutaneous coronary intervention (PCI) on angiographic and in-hospital clinical outcomes in an all-come patient population. They assessed consecutive unselected subjects who received cangrelor when the decision was made to undergo PCI. All patients made the transition to oral antiplatelet therapy at the end of the procedure. This study included 223 patients (244 lesions; 106, 97, and 20 patients with Thrombolysis in Myocardial Infarction flow grade [TIMI-Flow] 0/1, TIMI-Flow 2/3, and cardiogenic shock, respectively; mean age 63±12 years, 70% men; 38% diabetes mellitus). A total of 72% presented with acute myocardial infarction. When administered to unselected subjects undergoing PCI, the safety as well as the efficacy of cangrelor in restoring TIMI-Flow 3, reducing thrombus burden, and improving myocardial blush grade and TIMI-myocardial perfusion grade was supported. Considering cangrelor was recommended in patients with intracoronary thrombus before intervention.